95 related articles for article (PubMed ID: 10694841)
1. Interferon gamma production in blood lymphocytes correlates with disability score in multiple sclerosis patients.
Petereit HF; Richter N; Pukrop R; Bamborschke S
Mult Scler; 2000 Feb; 6(1):19-23. PubMed ID: 10694841
[TBL] [Abstract][Full Text] [Related]
2. Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis.
Durán I; Martínez-Cáceres EM; Brieva L; Tintoré M; Montalban X
Mult Scler; 2001 Jun; 7(3):151-6. PubMed ID: 11475437
[TBL] [Abstract][Full Text] [Related]
3. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA
Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436
[TBL] [Abstract][Full Text] [Related]
4. Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis.
Sepulcre J; Sanchez-Ibarrola A; Moreno C; de Castro P
Cytokine; 2005 Oct; 32(2):111-6. PubMed ID: 16246570
[TBL] [Abstract][Full Text] [Related]
5. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
6. Physical activity correlates with neurological impairment and disability in multiple sclerosis.
Motl RW; Snook EM; Wynn DR; Vollmer T
J Nerv Ment Dis; 2008 Jun; 196(6):492-5. PubMed ID: 18552627
[TBL] [Abstract][Full Text] [Related]
7. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
8. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
9. Natural history of multiple sclerosis: a unifying concept.
Confavreux C; Vukusic S
Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
[TBL] [Abstract][Full Text] [Related]
10. Relapses and progression of disability in multiple sclerosis.
Confavreux C; Vukusic S; Moreau T; Adeleine P
N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
[TBL] [Abstract][Full Text] [Related]
11. Measurement of intracellular cytokines in MS patients treated with beta-interferon and association of a beta-interferon induced exacerbation with increased expression of gamma-interferon by monocytes.
Toh L; Kilpatrick TJ
J Clin Neurosci; 2001 Sep; 8(5):434-6. PubMed ID: 11535012
[TBL] [Abstract][Full Text] [Related]
12. The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Frischer JM; Bramow S; Dal-Bianco A; Lucchinetti CF; Rauschka H; Schmidbauer M; Laursen H; Sorensen PS; Lassmann H
Brain; 2009 May; 132(Pt 5):1175-89. PubMed ID: 19339255
[TBL] [Abstract][Full Text] [Related]
13. [Phagocyte activity and the interferon system in patients with different types of multiple sclerosis].
Khanokh EV; Rozhdestvenskiĭ AS; Dolgikh TI; Ershov AV; Kakulia AV; Delov RA
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):21-4. PubMed ID: 21916155
[TBL] [Abstract][Full Text] [Related]
14. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
Szmyrka-Kaczmarek M; Pokryszko-Dragan A; Pawlik B; Gruszka E; Korman L; Podemski R; Wiland P; Szechinski J
Lupus; 2012 Apr; 21(4):412-20. PubMed ID: 22074845
[TBL] [Abstract][Full Text] [Related]
15. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
Sola P; Mandrioli J; Simone AM; Ferraro D; Bedin R; Annecca R; Venneri MG; Nichelli PF; Merelli E
Mult Scler; 2011 Mar; 17(3):303-11. PubMed ID: 21078694
[TBL] [Abstract][Full Text] [Related]
16. Altered frequency of T regulatory cells is associated with disability status in relapsing-remitting multiple sclerosis patients.
Bjerg L; Brosbøl-Ravnborg A; Tørring C; Dige A; Bundgaard B; Petersen T; Höllsberg P
J Neuroimmunol; 2012 Aug; 249(1-2):76-82. PubMed ID: 22608884
[TBL] [Abstract][Full Text] [Related]
17. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
Bates D
Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
[TBL] [Abstract][Full Text] [Related]
18. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
[TBL] [Abstract][Full Text] [Related]
19. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
20. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Vollmer TL; Wynn DR; Alam MS; Valdes J
Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
